Market Overview

UPDATE: Piper Jaffray Upgrades Celgene Corporation to Overweight on Reduced Revlimid Reliance

Share:
Related CELG
Portfolio Manager Says Now Is A Great Time To Buy Biotech
Lightning Round: Jim Cramer Is A Seller Of Pandora, Lost Faith In Chipotle
Your Daily Pharma Scoop: Exelixis Still Attractive, Portola's BevyxXa, Pluristem Patent (Seeking Alpha)

Piper Jaffray upgraded Celgene Corporation (NASDAQ: CELG) from Neutral to Overweight and raised the price target from $86.00 to $111.00.

Piper Jaffray noted, "We are upgrading CELG to Overweight from Neutral following positive top-line data from the Apremilast Phase III psoriasis studies and new 2017 guidance that supports a 25% annual EPS growth. We expect the streak of successful clinical studies and milestones, including Apremilast (psoriatic arthritis, psoriasis), Abraxane (lung cancer approval, melanoma, pancreatic), and pomalidomide (myeloma), to translate to meaningful top-line growth, lowering CELG's reliance on Revlimid performance."

Celgene Corporation closed at $85.73 on Monday.

Latest Ratings for CELG

DateFirmActionFromTo
Nov 2017BMO CapitalMaintainsOutperform
Oct 2017OppenheimerMaintainsOutperform
Oct 2017UBSMaintainsBuy

View More Analyst Ratings for CELG
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (CELG)

View Comments and Join the Discussion!

Partner Center